18 and older, female only, with Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline of Plasma Estradiol LevelsPrimary· Baseline to 9 weeks
Plasma estradiol levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma estradiol levels
Group
Value
95% CI
Fulvestrant
-1.26
-1.7 – -0.26
Change From Baseline of Tricuspid Annular Plane Systolic Excursion (TAPSE)Primary· Baseline to 9 weeks
Measure obtained from echocardiogram completed on participants Difference in change from baseline to 9 weeks in TAPSE
Group
Value
95% CI
Fulvestrant
2
-3 – 5.5
Change From Baseline of Six Minute Walk DistancePrimary· Baseline to 9 weeks
Measure obtained from six minute walk test completed by participants Difference in change from baseline to 9 weeks in the six minute walk test distance
Group
Value
95% CI
Fulvestrant
31
10 – 32
Change From Baseline of Plasma NT-proBNP LevelPrimary· Baseline to 9 weeks
Plasma NT-proBNP levels are obtained and measured from blood samples collected from each participant.
Difference in change from baseline to 9 weeks in plasma NT-proBNP levels
Group
Value
95% CI
Fulvestrant
42.1
6.7 – 114
Adverse events — posted to ClinicalTrials.gov
Time frame: 12 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The main purpose of this clinical trial is to examine the feasibility and effects of fulvestrant in post-menopausal women with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated. The study will evaluate changes in circulating hematopoietic progenitor cells, plasma hormone levels, NT-proBNP, and other plasma biomarkers after the administration of fulvestrant. Changes in tricuspid annular plane systolic excursion, stroke volume index, right ventricular fractional area change, and other echo parameters after fulvestrant administration will be evaluated as well as changes in distance walked in six minutes.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07570966 — Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and
· Phase 1, PHASE2
· not yet recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
· Phase 2
· recruiting
NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
· Phase 1
· recruiting
NCT07368998 — To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
· Phase 2
· recruiting
NCT07287917 — Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Pulmonary Arterial Hypertension
Currently open trials in the same condition.
NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)
· active not recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept
· Phase 2
· recruiting
NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension
· recruiting
NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
· recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec
· Phase 4
· recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
· EARLY_PHASE1
· not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD
· NA
· not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm
· Phase 2
· not yet recruiting
NCT07463131 — Negative Income Tax Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 9 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02911844.